secwatch.observer — SEC 8-K summary
======================================

Issuer:     Schrodinger, Inc. (SDGR)
CIK:        0001490978
Form:       8-K
Filed at:   2024-05-01T23:59:59+00:00
Accession:  0001490978-24-000045
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Schrödinger Q1 revenue $36.6M, net loss $54.7M; FDA clears IND for SGR-3515
---------------------------------------------------------------------------

- Total revenue $36.6M (down 44% YoY); software revenue $33.4M (+3.7%).
- Net loss $54.7M vs net income $129.1M in Q1 2023; non-GAAP net loss $62.4M.
- FDA cleared IND for SGR-3515 (Wee1/Myt1 inhibitor); Phase 1 solid tumors trial expected Q3 2024.
- SGR-1505 and SGR-2921 Phase 1 data readouts expected late 2024 or 2025.
- Rights to SOS1 inhibitor reverted from BMS after portfolio prioritization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1490978/000149097824000045/0001490978-24-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1490978/000149097824000045/sdgr-20240501.htm
  HTML page:      https://secwatch.observer/filing/0001490978-24-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer